跳至主要内容
临床试验/JPRN-UMIN000009698
JPRN-UMIN000009698已完成未知

Phase II crinical trial of cetuximab rechallenge with KRAS wild-type unresectable/recurrent colorectal cancer - Cetuximab Rechallenge

Okayama Molecular Target-Based Drugs Society for Cancer of the Colon and Rectum0 个研究点目标入组 25 人开始时间: 2013年1月7日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2)Patients with brain metastasis which have symptoms or patients with history of brain metastasis 3)Severe wattery diarrhea 4)Severe infectious disease 5)Severe complications (interstitial lung disease or pulmonary fibrosis, kidney failure, hepatic failure, uncontrolable diabetes, uncontrolable hypertension) 6)Severe carcinomatous ascites, pleural effusion or pericardial cavity effusion 7)Pregnant or lactating women or women of childbearing potential, and no birth-control 8)Patients with history of serious hypersensitivity

研究者

发起方
Okayama Molecular Target-Based Drugs Society for Cancer of the Colon and Rectum

相似试验